Trial · NCT02830776
Topical Bimatoprost for Chemical Blepharoplasty
NCT02830776, Early phase 1, Completed, Tulane University; results first posted 2021-03-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Bimatoprost for Chemical Blepharoplasty. Trials, record NCT02830776. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02830776
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Bimatoprost for Chemical Blepharoplasty
- NCT number
- NCT02830776
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 15 participants, actual
- Lead sponsor
- Tulane University
- Conditions
- Dermatochalasis
- Interventions
- bimatoprost 0.03% ophthalmic solution
- First posted
- 2016-07-13
- Last updated
- 2021-03-05
- Results first posted
- 2021-03-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Graded Change in Dermatochalasis | At 12 weeks | Patients were followed for 12 weeks total, with visits every 4 weeks for a total of 4 visits. Photodocumentation was performed at each visit. At completion of the study period, each patient's photographs at weeks 0 and 12, were graded by 2 blinded evaluators for level of dermatochalasis: -1 (deep upper eyelid sulcus), 0 (no dermatochalasis), 1 (mild, slightly noticeable), 2 (moderate, noticeable), or 3 (severe, distinctive). The change of dermatochalasis (week 12 score subtracted from week 0 score) was the primary outcome measure. A greater change (based on a higher score) in dermatochalasis indicated better response to the treatment. |
| Secondary | Change in Patient Satisfaction | Weeks 0, 12 | Entry and exit surveys were completed about self perception of the periocular area. The satisfaction was measured based on 2 short surveys. Entry survey had 1 question "how do you rate your satisfaction with your appearance?" - the scale was 0-5, with 0 being "Not at all" to 5 being "extremely." The exit survey posed two questions, (1) "how do you rate satisfaction with your appearance?" with the same 0-5 scale, as well as (2) Do you notice an improvement in your eyelid droop (dermatochalasis)?" with a scale as follows: Worse (-1), No Change (0), 25% better (1), 50% better (2), 75% better (3), or 100% better (4). The change in satisfaction was measured by the summation of scores from both surveys and the average was calculated. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Graded Change in Dermatochalasis | At 12 weeks | Patients received Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping) | units on a scale | MEAN |
| SECONDARY | Change in Patient Satisfaction | Weeks 0, 12 | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Graded Change in Dermatochalasis | Treatment Group | .2679 | 95% Confidence Interval 0.0970 to 0.4387 | units on a scale | |
| Change in Patient Satisfaction | Treatment Group | .214 | 95% Confidence Interval -.777 to .349 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment Group | 15 | |
| Overall Study | COMPLETED | Treatment Group | 14 | |
| Overall Study | NOT COMPLETED | Treatment Group | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Itching | Skin and subcutaneous tissue disorders | Treatment Group | 5 | 15 | |
| other | Eyelid skin redness | Skin and subcutaneous tissue disorders | Treatment Group | 4 | 15 | |
| other | Eyelid darkening | Skin and subcutaneous tissue disorders | Treatment Group | 3 | 15 | |
| other | Unexpected hair growth | Skin and subcutaneous tissue disorders | Treatment Group | 1 | 15 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Group | 0 | 15 |
| Total, other adverse events | Treatment Group | 7 | 15 |
| Total, serious adverse events | Treatment Group | 0 | 15 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02830776
GET https://conductscience.org/api/trials/v1/NCT02830776/registered